🔬 This research can enhance antibody production processes. The team uses CRISPR to manipulate glycosylation pathways.
💡 Identifying these new genes helps in developing targeted therapeutics. Their findings aim to control antibody quality efficiently.
📅 Expect more insights from Mijakovac at the Bioprocessing Summit Europe in March 2026!
Introduction:
Recent research conducted by scientists in Croatia has uncovered 90 genes that are associated with the glycosylation of immunoglobulin G (IgG). This discovery holds significant implications for antibody production processes and potential therapeutic applications.
- The identification of 90 genes involved in the regulation of IgG glycosylation was a result of extensive genome-wide association studies (GWAS) conducted over the last 10 to 15 years.
- Among these, 20 genes have demonstrated the ability to influence glycosylation pathways, presenting opportunities for optimization in antibody yield and production scalability.
- The team employed CRISPR technology to modify Human Embryonic Kidney (HEK) cell lines, enabling the examination of how these genes influenced protein production and subsequent effects on IgG glycosylation.
- Findings indicate that certain genes exert specific effects on IgG glycosylation, producing distinct glycoforms unlike results achieved through traditional enzyme modification.
- The ongoing research aims to elucidate the glycosylation pathways governed by these genes, potentially leading to enhanced therapeutic strategies targeting these regulatory mechanisms.
Conclusion:
The discovery of genes regulating IgG glycosylation introduces a new perspective for improving antibody production processes. Understanding these pathways could transform therapeutic development, enabling researchers and pharmaceutical companies to create more effective antibodies with desired glycosylation profiles, ultimately enhancing the efficacy of immunotherapeutic agents.
